King warned on Embeda VNRs

Share this article:
Video news releases (VNRs) for King's abuse-resistant pain drug Embeda drew a warning letter from FDA's Division of Drug Marketing, Advertising and Communications.

The agency said two VNRs omitted or minimized risks, including those featured in the drug's “extensive” Boxed Warning, and failed to present limitations to the approved indication. Moreover, the warning letter said King presented misleading claims – among them, those about the drug's alleged abuse-resistant properties, which have not been substantiated clinically.  

DDMAC said King agreed to pull the VNRs in August following a teleconference with regulators.

The analgesic, approved in August for the management of moderate to severe pain, contains morphine sulfate and carries a long boxed warning against potentially fatal consequences of abuse, use with alcohol and improper administration.

The agency demanded that the company furnish a list of promotional materials it has pulled, and that it disseminate corrective messaging to counteract the violative releases.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...